Contact Information: Contacts: Investor Relations. Andrew Barwicki 516.662.9461 Email Contact NanoLogix, Inc. 87 Stambaugh Avenue, Suite Two Sharon, PA 16146 Telephone: 724-346-1302 Fax: 724-346-9596 Website: www.nanologix.net
NanoLogix Achieves Initial Sales of Hydrogen Powered Generators
| Source: NanoLogix, Inc.
SHARON, PA -- (MARKET WIRE) -- February 9, 2007 -- NanoLogix, Inc. (PINKSHEETS : NNLX ), an industry
innovator in the research, development and commercialization of
nano-biotechnologies, applications and processes, announced today the
initial sale of hydrogen powered generator engines, which had been
converted from gas engines. This was done in conjunction with Precision
Performance Co. of Brookfield, Ohio, a private company.
Mitchell Felder, M.D., NanoLogix Chairman of the Board and Chief Executive
Officer, stated, "I am pleased our research and development have enabled us
to reach this company milestone. We have successfully converted gas powered
engines to hydrogen power. These initial sales will be recognized in the
first quarter of this year. Our sales initiatives will include small and
large projects, including motorcycles, diesel engines and numerous
combustion engines."
Precision Performance Co. in partnership with NanoLogix has successfully
converted gas powered engines to hydrogen power on numerous commercial
engines. NanoLogix has retained Precision Performance Co. to handle
conversion specifications based on the NanoLogix pending intellectual
property in this field of endeavor.
About NanoLogix, Inc.:
NanoLogix is an industry innovator in the research, development and
commercialization of nano-biotechnologies, applications and processes. The
Company owns or has the rights to 32 patented technologies. The Company is
currently focused on the production of hydrogen from agricultural
feedstock, industrial wastewater and municipal waste streams to create new
sources of energy. NanoLogix is presently operating a hydrogen bioreactor
at Welch's Food and has recently signed an agreement with the City of Erie
Wastewater Treatment Plant for a prototype bioreactor installation.
Additionally, NanoLogix develops and markets diagnostic test kits for use
in early detection of infectious human diseases such as cancer, cystic
fibrosis and AIDS, and owns a patent for the non-toxic induction of
apoptosis ('cell suicide') for the treatment of cancer. For more
information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.